US9101615 — Intravenous formulations of neurokinin-1 antagonists
Method of Use · Assigned to Opko Health Inc · Expires 2032-07-14 · 6y remaining
What this patent protects
This patent protects pharmaceutical compositions for intravenous administration of the compound ROLAPITANT HYDROCHLORIDE or its pharmaceutically acceptable salts, hydrates, or prodrugs.
USPTO Abstract
Pharmaceutical compositions for intravenous administration comprising the compound of Formula I or pharmaceutically acceptable salts, hydrates or prodrugs thereof are described herein. Methods of preparing the pharmaceutical compositions and methods for treating nausea and/or emesis with the pharmaceutical compositions are also described herein.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1741 |
— | rolapitant-hydrochloride |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.